What question did this study set out to answer?

To assess the efficacy of two starting doses of patiromer (8.4 g and 16.8 g) and evaluate its one-year safety in Japanese patients with hyperkalemia.

November 24, 2024Clinical and Experimental NephrologyOpen Access

Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study

View Full Paper

Ask AI

Bookmark

To assess the efficacy of two starting doses of patiromer (8.4 g and 16.8 g) and evaluate its one-year safety in Japanese patients with hyperkalemia.
Randomized 185 patients across three cohorts: non-dialysis patients with baseline serum potassium 5.1 to <6.0 mmol/L (NDC1, n=153) or 6.0 to <6.5 mmol/L (NDC2, n=10), and dialysis patients with 5.5 to <6.5 mmol/L (DC, n=22).
Evaluated NDC1 using a 1-week randomized, double-blind, placebo-controlled design followed by a 1-year open-label extension; NDC2 and DC underwent open-label treatment with dose titration up to 25.2 g.
At Week 1 in NDC1, least squares mean serum potassium change was -0.55 mmol/L (8.4 g) and -0.77 mmol/L (16.8 g) versus -0.10 mmol/L with placebo (P < 0.001 for each patiromer group vs. placebo).
More than 80% of patients across all cohorts achieved normal serum potassium levels by Week 5.
Patiromer was well tolerated over one year of treatment with no severe treatment-related adverse events.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized double-blind placebo-controlled trial demonstrates that patiromer reduces serum potassium in patients with hyperkalemia, suggesting a safe long-term management strategy.

Cite This Study

Kashihara et al. (2024) studied this question.

synapsesocial.com/papers/6a8861328dfe8b7ec5a54581 https://doi.org/10.1007/s10157-024-02585-5

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind placebo-controlled trial demonstrates that patiromer reduces serum potassium in patients with hyperkalemia, suggesting a safe long-term management strategy.

Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study

Key Points

Discussion

Implication

Cite This Study

Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider